182 related articles for article (PubMed ID: 22139687)
1. Assessment of reactive metabolites in drug-induced liver injury.
Lee KS; Oh SJ; Kim HM; Lee KH; Kim SK
Arch Pharm Res; 2011 Nov; 34(11):1879-86. PubMed ID: 22139687
[TBL] [Abstract][Full Text] [Related]
2. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.
Gómez-Lechón MJ; Tolosa L; Donato MT
J Appl Toxicol; 2016 Jun; 36(6):752-68. PubMed ID: 26691983
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.
Dragovic S; Vermeulen NP; Gerets HH; Hewitt PG; Ingelman-Sundberg M; Park BK; Juhila S; Snoeys J; Weaver RJ
Arch Toxicol; 2016 Dec; 90(12):2979-3003. PubMed ID: 27659300
[TBL] [Abstract][Full Text] [Related]
4. Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.
Xuan J; Chen S; Ning B; Tolleson WH; Guo L
Chem Biol Interact; 2016 Aug; 255():63-73. PubMed ID: 26477383
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced liver injury.
Holt M; Ju C
Handb Exp Pharmacol; 2010; (196):3-27. PubMed ID: 20020257
[TBL] [Abstract][Full Text] [Related]
6. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric assay using HepaRG cells for predicting drug-induced liver injury.
Tomida T; Okamura H; Satsukawa M; Yokoi T; Konno Y
Toxicol Lett; 2015 Jul; 236(1):16-24. PubMed ID: 25934330
[TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.
Smith KS; Smith PL; Heady TN; Trugman JM; Harman WD; Macdonald TL
Chem Res Toxicol; 2003 Feb; 16(2):123-8. PubMed ID: 12588182
[TBL] [Abstract][Full Text] [Related]
9. The Identification of Pivotal Transcriptional Factors Mediating Cell Responses to Drugs With Drug-Induced Liver Injury Liabilities.
Shah F; Medvedev A; Wassermann AM; Brodney M; Zhang L; Makarov S; Stanton RV
Toxicol Sci; 2018 Mar; 162(1):177-188. PubMed ID: 29106686
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.
Zhang J; Doshi U; Suzuki A; Chang CW; Borlak J; Li AP; Tong W
Chem Biol Interact; 2016 Aug; 255():3-11. PubMed ID: 26581450
[TBL] [Abstract][Full Text] [Related]
11. Current limitations and future opportunities for prediction of DILI from in vitro.
Funk C; Roth A
Arch Toxicol; 2017 Jan; 91(1):131-142. PubMed ID: 27766365
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins.
Usui T; Mise M; Hashizume T; Yabuki M; Komuro S
Drug Metab Dispos; 2009 Dec; 37(12):2383-92. PubMed ID: 19720731
[TBL] [Abstract][Full Text] [Related]
13. Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury.
Shimizu Y; Sasaki T; Yonekawa E; Yamazaki H; Ogura R; Watanabe M; Hosaka T; Shizu R; Takeshita JI; Yoshinari K
J Toxicol Sci; 2021; 46(4):167-176. PubMed ID: 33814510
[TBL] [Abstract][Full Text] [Related]
14. Role of cytochrome P450-mediated metabolism and involvement of reactive metabolite formations on antiepileptic drug-induced liver injuries.
Sasaki E; Yokoi T
J Toxicol Sci; 2018; 43(2):75-87. PubMed ID: 29479037
[TBL] [Abstract][Full Text] [Related]
15. [Drug-induced hepatits: the role of unstable metabolites (author's transl)].
Pessayre D; Benhamou JP
Acta Gastroenterol Belg; 1978; 41(9-10):574-86. PubMed ID: 735686
[No Abstract] [Full Text] [Related]
16. Editorial: Promising approaches to identify DILI drugs.
Li AP; Zhang J
Chem Biol Interact; 2016 Aug; 255():1-2. PubMed ID: 27393768
[No Abstract] [Full Text] [Related]
17. Signal transduction pathways involved in drug-induced liver injury.
Han D; Shinohara M; Ybanez MD; Saberi B; Kaplowitz N
Handb Exp Pharmacol; 2010; (196):267-310. PubMed ID: 20020266
[TBL] [Abstract][Full Text] [Related]
18. Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
Schadt S; Simon S; Kustermann S; Boess F; McGinnis C; Brink A; Lieven R; Fowler S; Youdim K; Ullah M; Marschmann M; Zihlmann C; Siegrist YM; Cascais AC; Di Lenarda E; Durr E; Schaub N; Ang X; Starke V; Singer T; Alvarez-Sanchez R; Roth AB; Schuler F; Funk C
Toxicol In Vitro; 2015 Dec; 30(1 Pt B):429-37. PubMed ID: 26407524
[TBL] [Abstract][Full Text] [Related]
19. Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury.
McEuen K; Borlak J; Tong W; Chen M
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640208
[TBL] [Abstract][Full Text] [Related]
20. Use of a systems model of drug-induced liver injury (DILIsym(®)) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice.
Howell BA; Siler SQ; Watkins PB
Toxicol Lett; 2014 Apr; 226(2):163-72. PubMed ID: 24560604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
